Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
07 2020
Historique:
received: 27 09 2019
accepted: 20 04 2020
pubmed: 21 5 2020
medline: 16 3 2021
entrez: 21 5 2020
Statut: ppublish

Résumé

To compare efficacy and safety of insulin glargine 300 units/mL (Gla-300) and 100 units/mL (Gla-100) in children and adolescents (6-17 years old) with type 1 diabetes. EDITION JUNIOR was a noninferiority, international, open-label, two-arm, parallel-group, phase 3b trial. Participants were randomized 1:1 to Gla-300 or Gla-100, titrated to achieve fasting self-monitored plasma glucose levels of 90-130 mg/dL (5.0-7.2 mmol/L), with continuation of prior prandial insulin. The primary end point was change in HbA In 463 randomized participants (Gla-300, Gla-300 provided similar glycemic control and safety profiles to Gla-100 in children and adolescents with type 1 diabetes, indicating that Gla-300 is a suitable therapeutic option in this population.

Identifiants

pubmed: 32430458
pii: dc19-1926
doi: 10.2337/dc19-1926
pmc: PMC7305011
doi:

Substances chimiques

Blood Glucose 0
Glycated Hemoglobin A 0
Hypoglycemic Agents 0
Insulin Glargine 2ZM8CX04RZ

Banques de données

figshare
['10.2337/figshare.12174711']
ClinicalTrials.gov
['NCT02735044']

Types de publication

Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1512-1519

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK045735
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Informations de copyright

© 2020 by the American Diabetes Association.

Auteurs

Thomas Danne (T)

Children's Hospital AUF DER BULT, Hannover Medical School, Hannover, Germany danne@hka.de.

William V Tamborlane (WV)

Department of Pediatrics, Yale University School of Medicine, New Haven, CT.

Oleg A Malievsky (OA)

Department of Pediatrics, Bashkir State Medical University, Ufa, Russian Federation.

Denise R Franco (DR)

CPCLIN Clinical Research Center, São Paulo, Brazil.

Tomoyuki Kawamura (T)

Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan.

Marek Demissie (M)

Sanofi, Frankfurt, Germany.

Elisabeth Niemoeller (E)

Sanofi, Frankfurt, Germany.

Harmonie Goyeau (H)

Sanofi, Chilly-Mazarin, France.

Marek Wardecki (M)

Sanofi, Warsaw, Poland.

Tadej Battelino (T)

UMC - University Children's Hospital and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH